What is Maxim Group’s Forecast for RMTI Q3 Earnings?

Rockwell Medical, Inc. (NASDAQ:RMTI) – Equities research analysts at Maxim Group issued their Q3 2026 earnings estimates for shares of Rockwell Medical in a report released on Tuesday, November 10th. Maxim Group analyst A. Vendetti anticipates that the company will post earnings per share of ($0.23) for the quarter. The consensus estimate for Rockwell Medical’s current full-year earnings is ($0.90) per share.

Rockwell Medical (NASDAQ:RMTI) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.11. The business had revenue of $19.12 million during the quarter, compared to analysts’ expectations of $18.22 million. Rockwell Medical had a negative net margin of 7.33% and a negative return on equity of 14.03%.

Other analysts have also recently issued reports about the company. Wall Street Zen upgraded Rockwell Medical to a “hold” rating in a report on Saturday, July 25th. Weiss Ratings upgraded Rockwell Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, October 8th. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Rockwell Medical in a report on Friday, September 11th. Finally, Zacks Research downgraded Rockwell Medical from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. One research analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, Rockwell Medical currently has an average rating of “Reduce” and a consensus target price of $20.00.

Rockwell Medical Trading Down 3.1%

NASDAQ RMTI opened at $7.08 on Thursday. The company has a quick ratio of 3.00, a current ratio of 3.25 and a debt-to-equity ratio of 0.21. Rockwell Medical has a fifty-two week low of $4.89 and a fifty-two week high of $12.90. The firm’s fifty day moving average price is $7.83 and its two-hundred day moving average price is $8.11.

Institutional Investors Weigh In On Rockwell Medical

A hedge fund recently bought a new stake in Rockwell Medical stock. Corsair Capital Management L.P. bought a new stake in Rockwell Medical, Inc. (NASDAQ:RMTI) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 50,000 shares of the company’s stock, valued at approximately $45,000. Corsair Capital Management L.P. owned about 0.13% of Rockwell Medical as of its most recent SEC filing. 23.31% of the stock is currently owned by institutional investors.

Rockwell Medical Company Profile

Rockwell Medical, Inc. is a healthcare company focused on developing, manufacturing and commercializing products used in the treatment of patients with end-stage renal disease (ESRD) who receive hemodialysis. The company supplies products intended to support anemia management and other aspects of dialysis care. Its principal pharmaceutical product is Triferic, an iron replacement therapy designed to deliver iron to hemodialysis patients through the dialysate. Rockwell Medical also markets Triferic AVNU, an intravenous formulation administered during hemodialysis.